10x Genomics, Inc. (NASDAQ ... just a few that have inspired and motivated our team recently. As featured in Nature last month, researchers relied on Chromium, Visium and Xenium to demonstrate ...

Parse Biosciences, the leader in accessible and scalable single cell sequencing, today affirmed their plans to proceed with development and future ...

Genomics announced that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences.

Whitaker, Chief Legal Officer of 10x Genomics. "We are pleased with this resolution on ATAC as we continue to defend the asserted Brenner patents on appeal." The company's litigation against Parse ...

Genomics (TXG) provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, in ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

PLEASANTON, Calif. - In a significant development in the biotechnology patent landscape, 10x Genomics Inc. (NASDAQ:TXG), currently valued at $1.2 billion, has successfully obtained a worldwide ...

Citi lowered the firm’s price target on 10x Genomics (TXG) to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly filed against Vizgen Inc. in 2022, alleging that Vizgen unlawfully used ...